Results of a Phase 1 Study of Quizartinib as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Stem Cell Transplant
This study demonstrated acceptable tolerability and early evidence of reduced relapse rate following allo‐HCT with quizartinib maintenance compared to historical cohorts. No MTD was identified, but 60 mg daily was selected as highest dose for continuous daily administration based on randomized comparison of daily 30 and 60 mg doses in relapsed/refractory AML. This article is protected by copyright. All rights reserved.
Source: American Journal of Hematology - Category: Hematology Authors: Brenda M. Sandmaier, Samer Khaled, Bet ül Oran, Guy Gammon, Denise Trone, Olga Frankfurt Tags: Research Article Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Anemia | Gastroenterology | Hematology | History of Medicine | Leukemia | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants